CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Alnylam Biotherapeutics has formed a Scientific Advisory Board. Alnylam Biotherapeutics is a division of Alnylam focused on advancing the applications of RNAi technology for manufacturing of biotherapeutics, such as recombinant proteins and monoclonal antibodies. Joining the Alnylam Biotherapeutics Scientific Advisory Board will be Daniel Anderson, Ph.D., Charles Cooney, Ph.D., and Robert Langer, Ph.D.
